US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Articles published by AbCellera Biologics Inc.

< Previous 1 2 3 4 Next >
News headline image
AbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
News headline image
AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
News headline image
AbCellera to Present at the Cantor Global Healthcare Conference on September 9, 2026
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
News headline image
AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
News headline image
AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
News headline image
AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
News headline image
AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
News headline image
AbCellera Reports Q2 2026 Business Results
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
News headline image
AbCellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL VRTX
News headline image
AbCellera to Report Second Quarter 2026 Financial Results on August 5, 2026
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
News headline image
AbCellera Appoints Dr. Lynn Seely to its Board of Directors
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
News headline image
Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL JAZZ
News headline image
AbCellera Appoints Dr. Victor Sandor to its Board of Directors
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
News headline image
AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
News headline image
AbCellera to Present at Upcoming Investor Conferences in May and June 2026
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
News headline image
AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
News headline image
AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
News headline image
AbCellera Reports Full Year 2025 Business Results
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
News headline image
AbCellera to Present at Upcoming Investor Conferences in March and April 2026
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
News headline image
AbCellera to Report Full Year 2025 Financial Results on February 24, 2026
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
News headline image
AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
News headline image
AbCellera and Bruker Reach Global Settlement of Patent Litigation
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
News headline image
AbCellera Appoints Dr. Stephen Quake to its Board of Directors
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
News headline image
AbCellera Reports Q3 2025 Business Results
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
News headline image
AbCellera to Participate at Upcoming Investor Conferences in November and December 2025
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
News headline image
AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
News headline image
AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
News headline image
AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
News headline image
AbCellera to Participate at Upcoming Investor Conferences in September
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
News headline image
AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
< Previous 1 2 3 4 Next >